National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedStone CA, Jr., Robinson LB, Li L
Clinical phenotypes of immediate first-dose reactions to mRNA COVID-19: a multicenter latent class analysis.
The objectives of this retrospective study were to define distinct clinical phenotypes of immediate reactions after dose 1 of mRNA COVID-19 vaccination, and to assess the relation of clinical phenotype to mRNA COVID-19 vaccine second dose tolerance. Researchers identified 265 patients who experienced dose-1 immediate reactions with 3 phenotype clusters: limited or predominantly cutaneous, sensory, or systemic. Of these, 223 patients received a second dose and 200 tolerated the second dose; sensory cluster (numbness or tingling) was associated with a higher likelihood of second dose intolerance, but this finding did not persist when accounting for objective signs.
AHRQ-funded; HS026395.
Citation: Stone CA, Jr., Robinson LB, Li L .
Clinical phenotypes of immediate first-dose reactions to mRNA COVID-19: a multicenter latent class analysis.
J Allergy Clin Immunol Pract 2023 Feb;11(2):458-65.e1. doi: 10.1016/j.jaip.2022.08.048.
Keywords: COVID-19, Medication, Adverse Drug Events (ADE), Adverse Events, Infectious Diseases, Vaccination
Banerji A, Norton AE, Blumenthal KG
Rapid progress in our understanding of COVID-19 vaccine allergy: a cause for optimism, not hesitancy.
This paper is a review of current understanding of COVID-19 vaccine allergy. Rapid progress has been made over the past several years in large part due to important research efforts from individuals in the allergy community. Better data has shown safety of repeat vaccination despite an initial reaction. The review ran from December 2020 through early 2022.
AHRQ-funded; HS026395; HS025375
Citation: Banerji A, Norton AE, Blumenthal KG .
Rapid progress in our understanding of COVID-19 vaccine allergy: a cause for optimism, not hesitancy.
J Allergy Clin Immunol 2022 Jul;150(1):12-16. doi: 10.1016/j.jaci.2022.03.023..
Keywords: COVID-19, Vaccination, Adverse Drug Events (ADE), Adverse Events
Caballero ML, Krantz MS, Quirce S
Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions.
In this paper, the authors provided a review of the evidence-based literature outlining epidemiology and mechanisms of excipient reactions and provided strategies for heightened recognition and allergy testing.
AHRQ-funded; HS026395.
Citation: Caballero ML, Krantz MS, Quirce S .
Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions.
J Allergy Clin Immunol Pract 2021 Aug;9(8):2968-82. doi: 10.1016/j.jaip.2021.03.002..
Keywords: Adverse Drug Events (ADE), Adverse Events, Medication, Medication: Safety, Vaccination, Patient Safety
Wang SV, Abdurrob A, Spoendlin J
Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines.
The need to develop methods for studying the safety of childhood immunization schedules has been recognized by the Institute of Medicine and Department of Health and Human Services. The recommended childhood immunization schedule includes multiple vaccines in a visit. A key concern is safety of concomitant (same day) versus separate day vaccination. This paper addressed a methodological challenge for observational studies using a self-controlled design to investigate the safety of concomitant vaccination.
AHRQ-funded; HS022193.
Citation: Wang SV, Abdurrob A, Spoendlin J .
Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines.
Pharmacoepidemiol Drug Saf 2018 Apr;27(4):405-12. doi: 10.1002/pds.4399..
Keywords: Adverse Drug Events (ADE), Adverse Events, Children/Adolescents, Patient Safety, Vaccination